The trial will test the safety, efficacy and dose tolerance in cancer patients with both managed and unmanaged pain.
The recruitment update coincides with separate positive feedback received from doctors who have been prescribing the medicine.
Feedback from some doctors is that it is proving effective in decreasing reliance on opioids and in its speed of action, aided by delivery through Medlab’s nano-particle spray, NanoCelle™
Under the Therapeutic Goods Administration’s (TGA) Special Access Scheme, Medlab has approval to supply NanaBis™ to medical practitioners for use with patients suffering cancer pain.
NanaBis™ is one of two developed formulas
Medlab has developed two cannabis-based medicines which have differing cannabis formulations, NanaBis™ and NanaBidial™.
NanaBis™ for those with chronic caner pain which is a whole cannabis plant extract of 1:1 ratios, CBD to THC
NanaBidial™ is for those suffering effects from chemotherapy is similar in all ways to NanaBis™ except the ratio is 18 parts CBD to 1 part THC.